Prof. Dr. İBRAHİM VEDAT BAYOĞLU | AVESİS

Akademik Veri Yönetim Sistemi

Yayınlar & Eserler

Makaleler 34

1. Prognostic Value of Treatment-Related Body Composition Changes in Metastatic NSCLC Receiving Nivolumab

KOCAASLAN E., Güren A. K., Akagündüz F., DEMİREL A., TUNÇ M. A., PAÇACI B., et al.

Medicina (Lithuania) , cilt.62, sa.1, 2026 (SCI-Expanded, Scopus)

2. Prognostic Value of Systemic Immune-Inflammation Index in Mucosal Malignant Melanoma

PAÇACI B., KOCAASLAN E., DEMİREL A., Akagündüz F., TUNÇ M. A., AĞYOL Y., et al.

Journal of Clinical Medicine , cilt.15, sa.2, 2026 (SCI-Expanded, Scopus)

3. Prognostic Value of 18F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab

KOCAASLAN E., Güren A. K., Akagündüz F., DEMİREL A., TUNÇ M. A., PAÇACI B., et al.

Journal of Clinical Medicine , cilt.15, sa.2, 2026 (SCI-Expanded, Scopus)

4. Adult-Onset Diffuse Midline Glioma, H3K27-Altered: A Genomics-Guided, Individualized, Multimodal Treatment Approach

Çelebi A., Yıldırım B., Yıldırım E., Işık S., ÇOBAN E., BIYIKLI E., et al.

Brain Sciences , cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)

5. FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)

Kalem A., Kus T., Sahin T. K., DİZDAR Ö., Efil S. C., Sendur M. A. N., et al.

Cancers , cilt.17, sa.17, 2025 (SCI-Expanded)

6. Association of TILs and HER2-low status with pathological response in triple-negative breast cancer

Deliktaş Onur İ., Kurukafa D., AĞYOL Y., Firat H. G., Sertesen Çamöz E., Türkel A., et al.

Medicine (United States) , cilt.104, sa.33, 2025 (SCI-Expanded)

7. Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)

Kalem A., Kus T., Gokcek S., ÜNEK İ. T., Sahin T. K., DİZDAR Ö., et al.

Journal of Clinical Medicine , cilt.14, sa.16, 2025 (SCI-Expanded)

8. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Kahraman S., Erul E., GÜMÜŞAY Ö., GÜVEN D. C., AKSOY S., BAŞARAN G., et al.

Clinical Breast Cancer , cilt.25, sa.5, 2025 (SCI-Expanded)

9. Clinicopathological Features and Survival Outcomes of Colorectal Cancer Patients Under 40 Years: A 20-Years Single-Center Experience

Kaan A., Demircan N. C., ÖZGÜR S. Ş., AKYOL T. B., majıdova n., Kocaaslan E., et al.

Uluslararası Hematoloji-Onkoloji Dergisi , cilt.35, sa.2, ss.104-111, 2025 (SCI-Expanded, Scopus, TRDizin)

10. Hormon reseptörü pozitif, HER2 negatif metastatik meme kanseri tanısıyla ribosiklib veya palbosiklib ile letrozol kombinasyon tedavisi verilen hastalarda HER2-düşük ekspresyonunun önemi

kahraman s., Hizal M., Gumusay O., Basaran G., Seyyar M., Sahin E., et al.

Turkish Journal of Clinics and Laboratory , cilt.16, sa.2, ss.255-262, 2025 (Hakemli Dergi)

11. Metastatik Kolorektal Kanser Tedavisinde Regorafenib Etkinliğini Etkileyen Prognostik Faktörler

SEVER N., bayoglu i. v.

Namık Kemal Tıp Dergisi , cilt.13, sa.2, ss.170-177, 2025 (Hakemli Dergi)

12. Evaluation of Pancreatic Atrophy in Patients with Hepatocellular Carcinoma Receiving Sorafenib Treatment

Kaan A., Zengin G., majıdova n., SEVER N., Ergelen R., Köstek O., et al.

Eurasian Journal of Medical Investigation , cilt.9, sa.1, ss.29-35, 2025 (Hakemli Dergi)

13. The Impact of Progesterone Receptor Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with First-Line CDK4/6 Inhibitors

Guliyev M., Güren A. K., Özge E., Çolak R., Majidova N., Alkan Şen G., et al.

Cancers , cilt.17, sa.4, 2025 (SCI-Expanded)

14. Lung Immune Prognostic Index (LIPI): Prognostic predictor for patients with extensive-stage small-cell lung cancer

Majidova N., Seyyar M., Guren A. K., Kocaaslan E., Kircali M. F., Sever N., et al.

Marmara Medical Journal , cilt.38, sa.1, ss.24-28, 2025 (ESCI)

15. The Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis

SEVER N., Yıldırım S., Gurbuz A. F., Karakaş Kılıç D., Zeynelgil E., Altintaş Y. E., et al.

Medicina (Lithuania) , cilt.61, sa.1, 2025 (SCI-Expanded)

16. Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study

Sekmek S., Ozsan Çelebi S. N., Bayram D., Erol C., Kos F. T., Sendur M. A. N., et al.

Scientific Reports , cilt.14, sa.1, 2024 (SCI-Expanded, Scopus)

Creative Commons License

17. Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group

AKYILDIZ A., GÜLTEKİN M., YİĞİT E., Demir E., Ismayilov R., Ahmed M., et al.

International Journal of Gynecological Cancer , cilt.34, sa.9, ss.1359-1365, 2024 (SCI-Expanded) Sürdürülebilir Kalkınma

Sürdürülebilir Kalkınma

18. Total Neoadjuvant Therapy Versus Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Real-World Study

Şenocak Taşçı E., Mutlu A. U., Saylık O., ÖLMEZ Ö. F., BİLİCİ A., Sünger E., et al.

Cancers , cilt.16, sa.18, 2024 (SCI-Expanded)

19. HER2 exon 20 mutant non-small cell lung cancer with complete remission of intracranial metastases with trastuzumab deruxtecan: A case report

Güren A. K., KOCAASLAN E., AĞYOL Y., Majidova N., Sever N., EREL P., et al.

Anti-Cancer Drugs , cilt.35, sa.8, ss.769-773, 2024 (SCI-Expanded, Scopus)

20. Evaluation of sarcopenia-associated survival in breast cancer with computed tomography-based pectoral muscle area measurements

KUZAN B. N., MAJIDOVA N., ILGIN C., ARSLAN H., KURŞUN M., ÖZGÜVEN S., et al.

MARMARA MEDICAL JOURNAL , cilt.37, sa.2, ss.178-184, 2024 (ESCI) Sürdürülebilir Kalkınma

Sürdürülebilir Kalkınma

21. The Role of Immune-Inflammation Biomarkers to Predict the Response of Nivolumab in Second Line Treatment of Advanced Stage Non-Small Cell Lung Cancer

Ozkul O., Sahin E., Cabuk D., SEVER N., majıdova n., bayoglu i. v., et al.

Eurasian Journal of Medical Investigation , cilt.8, sa.1, ss.58-66, 2024 (Hakemli Dergi)

Creative Commons License

22. Efficacy and Safety of Ixabepilone in Metastatic Breast Cancer After Multiple Treatments: Analysis Based on Real-World Data

Akdağ G., Alan Ö., Doğan A., Yildirim S., Kinikoğlu O., Majidova N., et al.

Journal of Oncological Science , cilt.10, sa.2, ss.89-96, 2024 (Scopus)

23. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing

KÖSTEK O., DEMİREL A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündogdu A., et al.

Journal of Chemotherapy , cilt.36, sa.7, ss.613-621, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

Sürdürülebilir Kalkınma

24. Systemic Inflammation Response Index and Pan-Immune-Inflammation Value: Prognostic Significance in Metastatic Melanoma

Majidova N., Kircali M. F., Güren A. K., Sever N., KOCAASLAN E., AĞYOL Y., et al.

Journal of Oncological Science , cilt.10, sa.3, ss.144-149, 2024 (Scopus, TRDizin)

25. Prognostic Factors Associated with Resected Osteosarcoma: Efficacy of Adjuvant Setting, Real-World Experience

Majidova N., ŞİMŞEK F., Biter S., YASLIKAYA Ş., Seyyar M., DUYGULU M. E., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.34, sa.1, ss.20-27, 2024 (SCI-Expanded, Scopus, TRDizin)

26. PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score

BAYOĞLU İ. V., Hüseynov J., Topal A., Sever N., Majidova N., Çelebi A., et al.

Journal of Clinical Medicine , cilt.12, sa.19, 2023 (SCI-Expanded)

Creative Commons License

27. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

KAHRAMAN S., ERUL E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., et al.

FUTURE ONCOLOGY , cilt.19, ss.727-736, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma

Sürdürülebilir Kalkınma

28. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Karacin C., Oksuzoglu B., Demirci A., KESKİNKILIÇ M., Baytemür N. K., Yılmaz F., et al.

BMC cancer , cilt.23, sa.1, ss.136, 2023 (SCI-Expanded)

Creative Commons License

Sürdürülebilir Kalkınma

29. Prognostic Significance of Mucinous Histology in Metastatic Colorectal Cancer Patients Treated with Regorafenib

ARIKAN R., Üstün H. S., Demircan N. C., Işik S., Telli T. A., Yaşar A., et al.

Journal of Oncological Science , cilt.9, sa.2, ss.53-61, 2023 (Scopus, TRDizin)

Creative Commons License

Sürdürülebilir Kalkınma

30. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study

YILDIRIM H. Ç., MUTLU E., Chalabiyev E., Ozen M., KESKİNKILIÇ M., ÖN S., et al.

BREAST , cilt.66, ss.85-88, 2022 (SCI-Expanded, Scopus)

Creative Commons License

31. Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma

AKIN TELLİ T., BUĞDAYCI O., Alan O., Sariyar N., Isik S., Arikan R., et al.

Nutrition and Cancer , cilt.74, sa.7, ss.2499-2507, 2022 (SCI-Expanded)

32. Varicella-Zoster Virus Infection and Brivudine Therapy: Unexpected Response in Sarcoma Patient

KÖSTEK O., Sari M., BAYOĞLU İ. V.

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , cilt.6, sa.2, ss.182-185, 2022 (ESCI, TRDizin)

33. The clinical and pathological features of 133 colorectal cancer patients with brain metastasis: a multicenter retrospective analysis of the Gastrointestinal Tumors Working Committee of the Turkish Oncology Group (TOG)

TANRIVERDİ Ö., Kaytan-Saglam E., Ulger S., Bayoglu İ. V., Turker I., Ozturk-Topcu T., et al.

MEDICAL ONCOLOGY , cilt.31, sa.9, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

Sürdürülebilir Kalkınma

34. Sunitinib for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Turkish Oncology Group Trial

Yildiz I., Ekenel M., Akman T., Kocar M., UYSAL M., Kanitez M., et al.

ANTICANCER RESEARCH , cilt.34, sa.8, ss.4329-4334, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

Sürdürülebilir Kalkınma

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 1

1. Breast cancer subtypes and the risk of distant relapse after breast conserving surgery or mastectomy: An Anatolian Society of Medical Oncology study.

Kaplan M. A., Urakci Z., Uncu D., Dane F., Ozkan M., Akman T., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) Sürdürülebilir Kalkınma

Sürdürülebilir Kalkınma

Metrikler

Yayın

37

Yayın (WoS)

28

Yayın (Scopus)

30

Atıf (WoS)

29

H-İndeks (WoS)

2

Atıf (Scopus)

85

H-İndeks (Scopus)

4

Atıf (Scholar)

1

H-İndeks (Scholar)

1

Atıf (TrDizin)

1

H-İndeks (TrDizin)

1

Atıf (Diğer Toplam)

1

Açık Erişim

7

BM Sürdürülebilir Kalkınma Amaçları